3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
3
Breast
3
Lymphoid
2
Genitourinary
1
Conditions
Prostatic Neoplasms
9
Hot Flashes
4
Urinary Bladder Neoplasms
2
Lymphoma, Follicular
2
Breast Neoplasms
2
Agnosia
2
Testicular Neoplasms
1
Teratoma, Testicular
1
Teratoma
1
Sezary Syndrome
1
Seminoma
1
Prostatic Hyperplasia
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Peripheral Nervous System Diseases
1
Pdgfra-Associated Chronic Eosinophilic Leukemia
1
Pain
1
Nocturia
1
Neuroblastoma
1
Neoplasms
1
Myeloproliferative Disorders
1
Mycosis Fungoides
1
Multiple Myeloma
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Neutrophilic, Chronic
1
Interventions
pembrolizumab
2
enfortumab vedotin
2
sagopilone
1
glutamic acid diethyl ester
1
allantoicase
1
Single Person
1
Prednisolone
1
Glutamine
1
Glutamic Acid
1
Exercise
1
Dietary Supplements
1
BID protein, human
1
Acupuncture Therapy
1
Acetylcarnitine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Peripheral Nervous System Diseases
×
Acupuncture Therapy
×
Genitourinary
×
Clear all
NCT07548476
2026-05-04
ACE
Dana-Farber Cancer Institute
Phase NA
Not yet recruiting
50 enrolled